Previous studies have suggested that ␣-glucosidase inhibitors such as castanospermine and deoxynojirimycin inhibit dengue virus type 1 infection by disrupting the folding of the structural proteins prM and E, a step crucial to viral secretion. We extend these studies by evaluating the inhibitory activity of castanospermine against a panel of clinically important flaviviruses including all four serotypes of dengue virus, yellow fever virus, and West Nile virus. Using in vitro assays we demonstrated that infections by all serotypes of dengue virus were inhibited by castanospermine. In contrast, yellow fever virus and West Nile virus were partially and almost completely resistant to the effects of the drug, respectively. Castanospermine inhibited dengue virus infection at the level of secretion and infectivity of viral particles. Importantly, castanospermine prevented mortality in a mouse model of dengue virus infection, with doses of 10, 50, and 250 mg/kg of body weight per day being highly effective at promoting survival (P < 0.0001). Correspondingly, castanospermine had no adverse or protective effect on West Nile virus mortality in an analogous mouse model. Overall, our data suggest that castanospermine has a strong antiviral effect on dengue virus infection and warrants further development as a possible treatment in humans.
Dengue fever, the most prevalent arthropod-borne viral illness in humans, is caused by dengue virus (DEN). DEN is a single-stranded, positive-polarity, enveloped RNA virus that is translated in the cytoplasm as a single polyprotein and cleaved into three structural and seven nonstructural proteins. Four related serotypes of DEN exist in nature and are transmitted to humans primarily by two mosquitoes, Aedes aegypti and Aedes albopictus. DEN is a member of the Flaviviridae family and is genetically related to the viruses that cause yellow fever, hepatitis C, and the Japanese, St. Louis, and West Nile encephalitides. DEN infection results in a spectrum of disease ranging from a debilitating, self-limited illness (dengue fever) to a life-threatening syndrome (dengue hemorrhagic fever [DHF] ). DEN causes disease globally with an estimated 25 to 100 million new infections per year (34) . At present, no vaccine has been approved for human use and treatment is supportive.
Flavivirus assembly takes place at the endoplasmic reticulum (ER) (7) . The structural glycoproteins prM and E localize to the luminal side of the ER and form an immature particle with prM and E in a heterodimeric complex (7, 58) . Furin-mediated proteolysis of prM in the trans-Golgi network (48) triggers rearrangement, homodimerization of E, and formation of the mature viral particle before release from the infected cell (1, 16) . In flavivirus-infected mammalian cells, a 14-residue oligosaccharide, (Glc) 3 (Man) 9 (GlcNAc) 2 , is added in the ER to specific asparagine residues on the prM and E proteins. This high-mannose carbohydrate is sequentially modified in the ER by resident ␣-glucosidases to generate N-linked glycans that lack the terminal ␣(1,2) and both ␣(1,3) glucose residues (19) . Recent experiments suggest that trimming of N-linked carbohydrates in the ER may be required for proper assembly or secretion of DEN (8, 55) .
Castanospermine is a natural alkaloid derived from the black bean or Moreton Bay chestnut tree (Castanospermum australae). The compound is water soluble and can be readily isolated in large quantity through a rather simple purification scheme (37) . In cells, castanospermine acts as an ER ␣-glucosidase I inhibitor and reduces infection of a subset of enveloped RNA and DNA viruses in vitro (DEN type 1 [DEN-1] [8] , bovine diarrhea virus [36, 54] , Sindbis virus [44] , cytomegalovirus [56] , human immunodeficiency virus [6, [49] [50] [51] [52] , and influenza virus [15, 38] ) and in vivo (herpes simplex virus [5] and Rauscher murine leukemia virus [40] ). Studies of its mechanism of action suggest that castanospermine may disrupt folding of some viral proteins by preventing the removal of the terminal glucose residue on N-linked glycans. A lack of modification of the high-mannose sugars on some viral proteins may inhibit requisite interactions with the protein folding chaperones calnexin and calreticulin (33, 57) . At least some flaviviruses appear sensitive to ␣-glucosidase inhibitors, such as castanospermine and deoxynojirimycin. Both drugs inhibited DEN-1 infection in BHK-21 cells (8) . Moreover, a related ␣-glucosidase inhibitor, N-nonyl-deoxynojirimycin, inhibited infection by DEN type 2 (DEN-2) more than that by Japanese encephalitis virus in BHK cells (55) .
In this study, we further evaluated the inhibitory activity of castanospermine against flaviviruses. We demonstrate that all serotypes of DEN were inhibited by castanospermine, yet yellow fever virus (YFV) and West Nile virus (WNV) were more resistant to the effects of the drug. Castanospermine acts by blocking the production and infectivity of DEN but not WNV or virus-like particles (VLP). Administration of castanospermine prevented mortality in mice even when DEN-2 was inoculated by an intracranial route. Our data suggest that castanospermine inhibits infection of a subset of flaviviruses and may have potential in vivo as an antiviral agent against DEN in humans. 20 , 3% bovine serum albumin, and 3% horse serum) for 1 h at 37°C. Viral supernatants from medium-or castanospermine-treated cells were clarified (14,000 ϫ g for 10 minutes), concentrated (SW41 rotor, 100,000 ϫ g for 2 hours at 4°C), and added to individual wells in duplicate for 2 hours at room temperature. Plates were washed four times in a biosafety hood with PBS supplemented with 0.05% Tween 20. Subsequently, biotinylated 4G2 (2 g/ml), a MAb that recognizes a cross-reactive epitope on all flavivirus E proteins (20) , was added for 1 hour at room temperature. After four additional washes in PBS with 0.05% Tween 20, horseradish peroxidase-conjugated streptavidin (2 g/ml; Zymed Laboratories, South San Francisco, CA) was added for 1 hour at room temperature. After six final washes with PBS, signal was detected after addition of TMB substrate (DakoCytomation, Carpinteria, CA) and 0.1 N H 2 SO 4 . Plates were evaluated at 450 nm on a 96-well plate reader (Genios Pro; Tecan Instruments, Reading, United Kingdom).
Quantitation of viral RNA. DEN and WNV viral RNAs were measured by fluorogenic reverse transcription-PCR (RT-PCR) with previously described virus-specific primers (21, 28) . Briefly, supernatants were harvested from mediumor castanospermine-treated cells 24 or 48 h after DEN or WNV infection and centrifuged (14,000 ϫ g for 10 min) to remove cellular debris. Carrier yeast tRNA (1 g/sample) was added to an aliquot (100 l) of supernatant, and viral RNA was recovered using the RNeasy minikit (Qiagen, Valencia, CA). Samples were processed using the TaqMan RT-PCR buffer system and an ABI 7000 sequence detection system (Applied Biosystems, Foster City, CA).
VLP production. Pseudoinfectious VLP that incorporate the prM-E proteins of different flaviviruses were produced by complementation of a subgenomic WNV replicon and will be described in greater detail elsewhere (T. Pierson, M. Sanchez, B. Puffer, A. Ahmed, B. Geiss, L. Valentine, L. Altamura, M. Diamond, and R. Doms, unpublished data). Briefly, BHK-rep-REN cells that stably propagate a subgenomic replicon of a lineage II strain of WNV encoding Renilla luciferase were transfected with two DNA expression vectors encoding capsid (C) and the prM-E proteins of WNV or DEN (DEN-1 strain; WestPac). In each case, the prM, E, and C proteins were derived from the homologous virus. Twelve hours after transfection, the medium was replaced with a low-glucose formulation of DMEM in the presence or absence of 500 M castanospermine. Supernatants containing infectious particles were harvested 30 hours later and clarified using 0.45-m syringe filters. Virus particles were concentrated by ultracentrifugation for 2 hours through a 20% sucrose cushion in an SW55 rotor at 40,000 rpm (4°C). Pelleted particles were resuspended in DMEM and used to infect preplated BHK-21 target cells in 96-well plates. Infection was assayed 40 hours postinfection by measuring Renilla luciferase activity (Promega) using a Trilux 1450 MicroBeta luminometer.
WNV and DEN subgenomic replicons. The lineage I WNV replicon plasmid pWN5ЈRucPur was generated from a genomic clone of the NY 1999 strain (plasmids pWN-AB1 and pWN-CG) provided by R. Kinney (Centers for Disease Control and Prevention, Fort Collins, CO). pWN5ЈRucPur was generated by deleting WNV nucleotides 181 to 2379 and fusing the first 31 amino acids of the C protein to a fusion protein containing Renilla luciferase (31), ubiquitin (3), and the puromycin N-acetyltransferase (PAC) gene (53) . The encephalomyocarditis virus internal ribosome entry site (4) was placed downstream of the PAC stop codon, so that translation of the WNV structural proteins begins at nucleotide 2380 (methionine 794). The DEN-2 replicon plasmid pD2-hRucPac was similarly generated from a genomic clone of the 16681 strain of DEN-2 (27) . pD2-hRucPac was created by deleting DEN-2 nucleotides 180 to 2342 and fusing the first 28 amino acids of the capsid protein with the Renilla luciferase, ubiquitin, and PAC genes as described above. The encephalomyocarditis virus internal ribosome entry site was placed downstream of the PAC stop codon and initiates translation of DEN nonstructural proteins at nucleotide 2343.
DNA template for replicon RNA transcription was prepared by linearization of pWN5ЈRucPur or pD2-hRucPac with XbaI restriction endonuclease followed by phenol-chloroform extraction and ethanol precipitation. Replicon RNA was generated using the Amplicap T7 High Yield Message Maker kit (Epicenter Technologies, Madison, WI). Ten micrograms of T7 RNA transcripts was electroporated into 5 ϫ 10 6 BHK-21 cells with a Bio-Rad Gene Pulser II with 1 pulse at 1.5 kV at 25 F. Replicon-containing cells were stably selected with 3-g/ml puromycin (Sigma-Aldrich, St. Louis, MO). BHK pWN5ЈRucPur cells or pD2-hRucPur cells were seeded into a 96-well plate at 2,000 cells/well without puromycin. One day later the medium was changed, and increasing concentrations of castanospermine were added. Cells were incubated in the presence of drug for 48 h, washed, and assayed for marker gene expression using a Renilla luciferase assay kit (Promega Corp., Madison, WI).
Mouse infections. A/J mice (28 to 31 days old) were infected with 10 5 PFU of mouse-adapted DEN-2 via the intracranial route. C57BL/6 (8-week-old) mice were infected by footpad inoculation with 10 2 PFU of WNV. 
RESULTS

Inhibition of virus infection in Huh-7 and BHK-21 cells.
Previous studies suggested that castanospermine, a pharmacological inhibitor of ER ␣-glucosidases, blocks trimming of Nlinked carbohydrates and abrogates DEN-1 infection by preventing proper processing of the envelope glycoproteins (8) . As a first step towards evaluating the utility of castanospermine as a broad-spectrum antiviral against DEN, we assessed its ability to inhibit the DEN-2 strain 16681, which replicates efficiently in a range of cell lines including BHK-21 and Huh-7 cells (11) . Treatment of cells with castanospermine inhibited the yield of infectious virus in a dose-dependent manner (Fig.  1A , B, and C). A higher concentration of castanospermine was required to inhibit the production of infectious DEN-2 in the Huh-7 human hepatoma cell line (50% inhibitory concentration [IC 50 ], 85.7 M) than in BHK-21 cells (IC 50 , 1 M). The IC 50 of castanospermine in BHK-21 cells was relatively independent of the inoculating dose of DEN, as similar values were observed over a broad range of multiplicities of infection (Fig.  1B) . As observed previously in Neuro 2a cells (8) , castanospermine treatment efficiently slowed the electrophoretic mobility of DEN prM, one of the glycosylated structural proteins. This difference in size between medium-and castanosperminetreated cells was restored after incubation of both proteins with endo H glycosidase (Fig. 1D) .
Inhibitory effect of castanospermine on other DEN serotypes, WNV, and YFV. For castanospermine to be considered as a useful anti-DEN agent it should be highly active against all DEN serotypes. Treatment of BHK-21 cells with castanospermine strongly inhibited virus secretion and cell-to-cell spread of strains from all four DEN serotypes ( Fig. 2A and B) . Because prior studies with N-nonyl-deoxynojirimycin (55) , another ER ␣-glucosidase inhibitor, had shown that DEN-2 appeared more sensitive to inhibition than Japanese encephalitis virus, we tested the inhibitory activity of castanospermine against two other clinically relevant flaviviruses, WNV and YFV. Interestingly, comparable or even high doses (500 M) of castanospermine had little, if any, significant inhibitory effect on WNV infection of BHK-21 cells. In contrast, an inter- mediate phenotype was observed with YFV. Treatment with 50 and 500 M castanospermine resulted in a 57 and 93% reduction, respectively, in the number of cells that expressed YFV antigen, as determined by flow cytometry (Fig. 2C) . A similar pattern was observed when infectious virus was measured by plaque assay of supernatants from virus-infected cells: 50 M castanospermine reduced WNV, YFV, and DEN production by 1.7-, 6.8-, and 910-fold, respectively (data not shown). Thus, castanospermine differentially inhibited infection of related flaviviruses even within the same cell type.
Effect of castanospermine on viral RNA replication. As a first step towards confirming its mechanism of action, we assessed the effect of castanospermine on viral replication. To separate viral replication from infectious virus production, we studied the effect of castanospermine on the replication of subgenomic replicons. BHK-21 cell lines were generated that autonomously replicate WNV and DEN subgenomic replicons. These replicons contain marker (e.g., luciferase) and nonstructural genes but lack structural genes and thus do not form viral particles. Treatment of replicon-expressing cells with MPA, a previously described inhibitor of DEN viral replication (13), reduced replicon propagation and marker gene expression by 98% (Fig. 3A) . In contrast, treatment of BHK-21 cells with castanospermine (range, 15 to 500 M) for 48 h reduced marker gene expression or propagation of WNV or DEN replicons modestly by up to 20 to 40%, respectively (Fig. 3A) . Because the reduction of luciferase activity was comparable to the slight effect of ␣-glucosidase inhibitors on overall host protein synthesis (8) , there is likely little, if any, direct effect of castanospermine on viral RNA replication and translation.
Castanospermine inhibits infectivity of DEN VLP and viruses. Previous studies have suggested that castanospermine may inhibit infection by interfering with the correct folding of DEN-1 envelope proteins (8) . One group hypothesized that castanospermine attenuated DEN infection by inhibiting a required association with the molecular chaperonin calnexin (55) . Based on these hypotheses, virion morphogenesis and secretion of infectious virus may be blocked by castanospermine. To test this, we produced pseudoinfectious VLP incorporating the envelope (prM-E) and capsid (C) proteins of DEN or WNV and a WNV replicon encoding a Renilla luciferase reporter gene. Pseudoinfectious VLP were produced in the presence and absence of castanospermine and used to infect BHK-21 cells. Virus entry was measured as a function of luciferase reporter gene activity. Treatment of cells producing these particles with castanospermine had little significant effect on the infectivity of WNV particles but reduced DEN particles by greater than 95% (Fig. 3B) . Because castanospermine only 
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To better define the stage of infection that was primarily inhibited by castanospermine, we evaluated its effect on the viral RNA-to-infectivity ratio in supernatants from infected cells. Supernatants were harvested from DEN-or WNV-infected BHK-21 cells, centrifuged to remove cellular debris, and analyzed by viral plaque assay. In parallel, viral RNA was extracted and measured by fluorogenic RT-PCR. As expected, at 24 or 48 h after infection, castanospermine treatment had small effects on the secretion of infectious WNV or viral particles containing WNV RNA in the supernatant (Fig. 4A and data not shown). As a result, there was no significant effect on the ratio of WNV viral RNA to PFU (medium, 1.7 ϫ 10 4 Ϯ 0.4 ϫ 10 4 ; 100 M castanospermine, 1.8 ϫ 10 4 Ϯ 0.4 ϫ 10 4 ; 500 M castanospermine, 1.4 ϫ 10 4 Ϯ 0.2 ϫ 10 4 ; P Ͼ 0.5). In contrast, at 24 and 48 h, castanospermine treatment markedly decreased the amount of DEN viral RNA and infectious virus in the supernatant (Fig. 4B and data not shown) . By 48 h, castanospermine had reduced the levels of DEN viral RNA and infectious virus by ϳ20-fold (P Յ 0.002) and 3,000-fold (P As baseline, the WNV replicon replicates at a ϳ10-foldhigher rate than does the DEN-2 replicon. The effect of mycophenolic acid (MPA; 10 g/ml) is shown as an example of an inhibitor that directly blocks replication of DEN-2 and WNV (13) . The data are from one representative experiment of three performed in quintuplicate, and the error bars reflect standard deviations. (B) The effect of castanospermine on infectivity of pseudotyped VLP. A stable BHK cell line expressing a WNV subgenomic replicon containing a luciferase gene was transfected transiently with the structural proteins of WNV or DEN-1 and then incubated in the presence or absence of castanospermine (500 M). Pseudotyped VLP were purified from supernatants by sucrose gradient centrifugation and added to new BHK cells for 40 h. Cells were lysed, and Renilla luciferase activity was measured. Relative infectivity of each VLP preparation was measured using triplicate infections, and the error bars reflect standard deviations. The data are from one representative independent experiment of three performed. In addition, DEN particles were measured using a two-MAb (anti-prM and biotinylated anti-E) trap ELISA (see Materials and Methods). The data were analyzed as described above.
Յ 0.05), respectively, and thus increased the viral RNA-to-PFU ratio by ϳ150-fold (medium, 1.0 ϫ 10 2 Ϯ 0.8 ϫ 10 2 ; 100 M castanospermine, 1.7 ϫ 10 4 Ϯ 0.7 ϫ 10 4 ; 500 M castanospermine, 1.5 ϫ 10 4 Ϯ 0.5 ϫ 10 4 ; P Յ 0.05). Based on the change in the ratio of DEN viral RNA to PFU in the supernatant of infected cells, our data suggested that castanospermine dominantly inhibited DEN by reducing the relative infectivity of secreted DEN particles. To assess this directly, we modified an antigen-capture ELISA (S. Hanna, T. Pierson, and R. Doms, unpublished results) to measure intact DEN viral particles from supernatants of infected cells. After clarification and ultracentrifugation, DEN particles were trapped by an anti-prM MAb (2H2) and detected with a biotinylated anti-E MAb (4G2). Notably, treatment with castanospermine markedly inhibited the total number of DEN particles in supernatants from infected cells, but not to the extent that infectivity was reduced (Fig. 4B) . Taken together, our data suggest that castanospermine inhibits DEN infection by reducing the numbers of secreted particles and, to a greater extent, decreasing the infectivity of the secreted DEN particles.
Effect of castanospermine in vivo against DEN and WNV. To further evaluate the protective activity of castanospermine, we assessed its ability to prevent mortality in highly lethal DEN and WNV challenge models in mice. A/J mice infected intracranially with 10 5 PFU of a mouse-adapted DEN-2 strain uniformly developed hind limb paralysis and succumbed to fatal central nervous system infection within 11 days of inoculation (Fig. 5A) . A/J mice that were treated with castanospermine for 10 days showed marked reduction in morbidity and mortality. A/J mice treated with 0.2 mg (10 mg/kg of body weight), 1 mg (50 mg/kg), and 5 mg (250 mg/kg) per day had survival rates of 25, 90, and 85%, respectively, whereas mice treated with vehicle had a 0% survival rate (Fig. 5A , P Ͻ 0.0001 for all three doses). Of note, higher doses of castanospermine (25 mg or 1.25 g/kg) caused adverse effects including diarrhea and weight loss (data not shown). Given its efficacy in preventing lethal DEN infection in mice, we also tested its inhibitory activity, in vivo, against WNV. Based on the in vitro studies, we predicted that castanospermine would not significantly inhibit WNV-induced mortality. Moreover, because WNV infection is more severe in immunocompromised mice (12) , if castanospermine had even a mildly immunosuppressive effect, we would expect increased mortality rates. Interestingly, treatment of mice with several doses of castanospermine had no effect, adverse or beneficial, on mortality after WNV infection (Fig. 5B and data not shown) .
DISCUSSION
Despite the significant disease burden caused by various members of the genus Flavivirus, no specific antiviral therapy is currently licensed for treatment. A prior study reported that the plant alkaloid castanospermine, an ER ␣-glucosidase inhibitor, blocked DEN-1 infection in BHK cells (8) and that this inhibition resulted from misfolding of structural glycoproteins. In this study, we extended this analysis by demonstrating the antiviral activity of castanospermine against all four serotypes of DEN. The inhibition of carbohydrate modification caused by castanospermine directly blocked the secretion and infectivity of DEN but not WNV viral particles. As a first step towards evaluating its therapeutic potential against DEN, we tested the efficacy of castanospermine in vivo. Treatment with castanospermine prevented mortality in mice after DEN infection, yet correspondingly had no effect against WNV. The lack of any effect against WNV infection in mice suggests that castanospermine does not have immunosuppressive effects, as small deficits in the innate and adaptive immune responses cause increased morbidity and mortality in this model (12) .
Castanospermine inhibited infection and viral spread of all four serotypes of DEN whereas infection by WNV was virtually unaffected by the compound. Moreover, partial inhibition of infection or VLP production was observed with YFV. Pre- 5 PFU of DEN-2. Mice were treated with saline vehicle or increasing concentrations (200 g, 1 mg, and 5 mg per day) of castanospermine as a single dose for 10 consecutive days. The survival curves were constructed using data from three independent experiments. The number of animals for each castanospermine dose ranged from 30 to 45 for each treatment group. The difference in survival curves was statistically significant for doses of drug shown (P Յ 0.0001). (B) Effect of castanospermine on WNV-induced mortality in C57BL/6 mice. Seven-week-old C57BL/6 mice were inoculated with 10 2 PFU of WNV via the footpad. Mice were treated with saline vehicle or 5 mg per day of castanospermine for 10 days. The survival curves were constructed using data from two independent experiments, and there was no significant statistical difference between vehicle and castanospermine treatment (P Ͼ 0.6).
VOL. 79, 2005 CASTANOSPERMINE INHIBITS DENGUE VIRUS INFECTION 8703
at Penn State Univ on April 16, 2008 jvi.asm.org vious studies have documented that ␣-glucosidase inhibitors reduce infection of many but not all RNA and DNA viruses (32) . One hypothesis as to the selectivity of castanospermine is that the drug inhibits viruses that require carbohydrate modification and glycoprotein oligomerization as a key step in the viral life cycle (39) . Surprisingly, as the structural glycoproteins, prM and E, of all flaviviruses undergo similar oligomerization, and yet clearly WNV was not susceptible to inhibition, this explanation may not apply to flaviviruses. In studies by other groups, the cell type has been shown to affect the susceptibility of vesicular stomatitis virus to castanospermine. This variation has been attributed to a Golgi apparatus-resident endomannosidase that circumvents castanospermine inhibition by cleaving an ␣-1,3-mannose bond to release oligosaccharides (25) . Interestingly, the BHK-21 and human hepatoma cell lines used in our study, which showed castanospermine-mediated inhibition of DEN, express high levels of this Golgi apparatus-resident endomannosidase (25) . The variation in susceptibility to castanospermine among flaviviruses also could be related to a differential requirement for association with the chaperones calnexin and calreticulin. Previous studies have suggested that ␣-glucosidase inhibitors interrupt the interaction between viral structural proteins and calnexin (18, 55) . At least one of the glycans on the prM or E of DEN, but not other flaviviruses, may be essential for calnexin-mediated protein folding, oligomerization, and virion assembly (55) . However, the ability to generalize from these results remains uncertain, as experiments by another group suggest that DEN structural proteins do not associate with chaperones in infected cells (8) .
The stringency of ER retention sequences in flavivirus envelope protein transmembrane domains could also explain the differential susceptibility to castanospermine. Flaviviruses that are more strongly retained in the ER would be more susceptible because they do not appreciably traffic through the Golgi network and encounter the resident "escape" mannosidase that allows carbohydrate processing and proper viral protein folding. Alternatively, a difference in transit time through the Golgi network among flaviviruses could affect exposure to "escape" mannosidases. However, at present, there are no data to support the idea that different flaviviruses have altered mechanisms for maturation and transit from the ER through the Golgi network, to the cell surface. Finally, the N-linked glycosylation of prM and E could be less critical for WNV infectivity than for that of DEN. Recent studies would suggest otherwise, as the loss of the N-linked glycosylation site on the WNV E protein was also associated with decreased viral infection in vitro (43) and in vivo (2, 45) . Mutagenesis and chimerization studies among flavivirus envelope proteins will be necessary directly to test the validity of these hypotheses.
Our complementary studies with DEN and WNV subgenomic replicons and VLP demonstrate that castanospermine has little specific effect on viral RNA replication and/or translation but a dominant effect on viral particle secretion and/or infectivity. Although recent studies have suggested that the glycosylation state of NS1, a cofactor for flavivirus RNA-dependent replication (26, 29, 30) , can modulate virus production (9, 35) , the carbohydrate modifications that are inhibited by castanospermine do not have a major impact on viral replication. Consistent with this, our experiments with infectious virus demonstrate that castanospermine inhibits DEN infection both at the level of secretion and at the level of infectivity of viral particles. Significant quantities of viral RNA were detected in supernatants of castanospermine-treated cells despite relatively few infectious particles, leading to a ϳ150-fold increase in the ratio of viral RNA to infectious virus. Moreover, our DEN particle capture ELISA experiments suggest that castanospermine reduced the infectivity of the secreted particles to a greater extent than secretion. Future studies will be required to determine exactly how castanospermine decreases the infectivity of DEN viral particles, i.e., whether the changes in carbohydrate modification affect virus attachment, entry, or uncoating.
In nature, DEN infection occurs between mosquitoes and humans. Although mice can be experimentally infected and become ill after DEN infection (17, 22, 23, 46, 47) , they do not develop a pathological syndrome that resembles DHF. Nonetheless, despite being imperfect for the study of pathogenesis of DEN infection, the mouse model provides important information on the toxicity of an antiviral drug as well as its ability to inhibit viral replication and prevent viral dissemination in vivo. As an initial test of its antiviral potential in humans, castanospermine improved survival rates in mice even when DEN was inoculated intracranially. Castanospermine was well tolerated and prevented DEN-associated mortality over a broad range of doses from 10 to 250 mg/kg/day. Doses in excess of 250 mg/kg/day in mice were associated with gastrointestinal toxicity, results that are consistent with previous observations in rats (42) . The treatment success with castanospermine was in spite of the relatively unfavorable pharmacokinetics, as the rate of its renal clearance in mice is up to 20 times higher than in humans (24) .
In summary, the ER ␣-glucosidase inhibitor castanospermine is a promising antiviral agent against DEN infection, with clear evidence of in vitro and in vivo activity. Castanospermine reduced secretion and viral infectivity and improved survival rates in mice. As it is derived quite readily from trees that can be grown in tropical climates, it is intriguing to consider castanospermine as a possible affordable therapeutic agent in the regions of the globe that have the greatest DEN morbidity and yet are pressed for health care resources. Based on the preclinical data presented here, we believe that further development of castanospermine is warranted as a possible treatment for DEN infection.
